Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach
-
Published:2024-11
Issue:11
Volume:37
Page:100589
-
ISSN:0893-3952
-
Container-title:Modern Pathology
-
language:en
-
Short-container-title:Modern Pathology
Author:
Fassan MatteoORCID,
Kuwata Takeshi,
Matkowskyj Kristina A.,
Röcken Christoph,
Rüschoff Josef
Reference62 articles.
1. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma;Klempner;Clin Cancer Res,2023
2. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma;Sahin;Ann Oncol,2021
3. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study;Türeci;Ann Oncol,2019
4. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial;Shitara;Lancet,2023
5. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial;Shah;Nat Med,2023